Bausch + Lomb acquired Whitecap Biosciences to develop therapies for glaucoma and geographic atrophy, aiming to improve visual outcomes. Whitecap's WB007, an alpha-2 adrenergic agonist, showed IOP ...

Jersey City-based Character Biosciences, a company specializing in genetics-guided drug discovery and development, has announced a collaboration with Bausch + Lomb, a leading global eye health company ...

The collaboration may expand into other ocular conditions. Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments for age ...

It provides range of vision beyond one focal point. Bausch + Lomb launched the enVista Aspire monofocal and toric IOLs in the European Union, according to a press release. Using intermediate ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic atrophy (GA). The early-stage deal breaks down like this: City gets an ...

City Therapeutics, Inc. set to collaborate with Bausch + Lomb on the development of a novel therapy for the treatment of retinal diseases including geographic atrophy (GA). The arrangement of this ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate ...

VAUGHAN, Ontario, January 13, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire ...